From June 27 to 28, 2022, the 4th Biomedicine Future Leaders Summit 2022 was held in Shenzhen, Guangdong, as scheduled. Professor Shi Yuanyuan, the founder of Shenzhen Cell Valley, was invited to participate in the meeting and published "Retrovirus or Lentivirus? That is the question." This is a wonderful keynote speech to discuss the industrial production of different virus vectors in cell therapy. 2022年6月27日—28日，Biofuture 2022第四屆生物醫(yī)藥未來領袖峰會在廣東深圳如期舉行，深圳細胞谷創(chuàng)始人史淵源教授受邀參會，并發(fā)表題為《Retrovirus or Lentivirus? That is the question.》（逆病毒還是慢病毒載體？這是個問題。）的精彩主題演講，探討不同的病毒載體在細胞治療中的工業(yè)化生產問題。

    The 21st century is the era of cell therapy. Due to the high threshold of retroviral vector technology, only a few enterprises in the world have mastered the industrial production technology of retroviral vector. Shenzhen Cell Valley is the only company in China that can produce clinical and industrial retroviral vectors. At the summit, Professor Shi Yuanyuan traced the development history of retroviral vector and lentiviral vector in view of the long-standing dispute over whether to use retroviral vector or lentiviral vector; The advantages of retrovirus vector compared with lentivirus vector in industrial production such as production cost, production mode, amount of packaging plasmid, quality control, and transduction efficiency were explained.21世紀是細胞治療的時代，由于逆病毒載體技術門檻較高，全球只有少量企業(yè)掌握了逆病毒載體工業(yè)化生產技術，而深圳細胞谷是國內唯一可生產臨床級及工業(yè)級逆轉錄病毒載體的公司。在此次峰會上，史淵源教授針對長久以來關于使用逆病毒載體還是慢病毒載體這個爭議問題上，追溯了逆病毒載體與慢病毒載體的發(fā)展歷史；講解了逆病毒載體相對于慢病毒載體在生產成本、生產方式、包裝質粒用量、質量控制、轉導效率等工業(yè)化生產優(yōu)勢。

    隨后，重點介紹了逆病毒載體在生產成本方面的巨大優(yōu)勢—逆病毒載體所需質粒用量為慢病毒載體所需質粒用量的千分之一，大大縮減了其生產成本。同時，史淵源教授從逆病毒及慢病毒載體在基因組中的插入方式及對內源基因表達的影響等角度，解釋了逆病毒載體與慢病毒載體用于細胞治療產品生產的安全性。根據(jù)最新的全球臨床研究表明，在CAR-T等細胞治療的安全性研究中，逆病毒和慢病毒兩種載體表現(xiàn)出了同樣好的安全性，打破了以往國內研發(fā)者們認為的逆病毒安全性存在問題的傳統(tǒng)觀念。Then, the great advantage of retroviral vector in production cost was introduced emphatically - the amount of plasmid required by retroviral vector was one thousandth of that required by lentiviral vector, which greatly reduced its production cost. At the same time, Professor Shi Yuanyuan explained the safety of retrovirus and lentivirus vectors used in the production of cell therapy products from the perspectives of the insertion mode of retrovirus and lentivirus vectors in the genome and their impact on endogenous gene expression. According to the latest global clinical research, in the research on the safety of cell therapy such as CAR-T, retrovirus and lentivirus have shown the same good safety, breaking the traditional idea that retrovirus safety is problematic, which was previously believed by domestic researchers.

    After Professor Shi Yuanyuan's wonderful sharing, many relevant scholars and experts in the field of cellular immunotherapy held a heated discussion and actively raised questions. Professor Shi Yuanyuan answered the relevant questions one by one. It also showed the domestic counterparts in the field of cell therapy that the current international R&D pipeline using retroviral vectors has exceeded the survey data of lentiviral vectors, which brought many new ideas and inspiration to the audience and won warm applause from the audience.史淵源教授的精彩分享結束后，眾多細胞免疫治療領域的相關學者、專家展開熱烈討論并積極提出問題，史淵源教授針對相關問題進行了一一解答。并向國內細胞治療領域的同行們展示了當前國際上使用逆病毒載體的研發(fā)管線已經超過了慢病毒載體的調研數(shù)據(jù)，為在場觀眾們帶來了很多新的理念和啟發(fā)，贏得了在場觀眾熱烈的掌聲。